Clinical Trial Activity Report (CTAR) 2024

Report highlights international confidence in Australian clinical trials

Global investment in Australian clinical trials is strong, with two thirds of Australian clinical trials, reviewed by Bellberry, funded by international companies according to its 2024 Clinical Trials Activity Report (CTAR).

Bellberry is Australia’s largest ethics and scientific reviewer of research involving humans reviewing approximately 40% of CTN (Clinical Trial Notification) trials in Australia.

Every year since 2019, Bellberry has released its Clinical Trial Activity Report (CTAR) to coincide with International Clinical Trials Day on 20 May. The CTAR describes the portfolio of research conducted in the prior year with Bellberry oversight.

Bellberry’s CEO, Kylie Sproston, says the 2024 data shows that Australia is uniquely placed to attract worldwide investment in clinical trials activity due to the high quality of its healthcare institutions and researchers.

“The 2024 Clinical Trial Activity Report shows that early phase trial activity remains a key strength with significant and continued growth over the last six years,” said Ms Sproston.

“The USA is the largest driver of early phase trials conducted in Australia, with Australia coming second and China third. Other top 10 countries include Germany, South Korea, Switzerland, the UK, Canada, France and Japan,” she said.

“Almost 50 per cent of the trials that Bellberry reviews are First in Human or Phase 1 trials, highlighting Australia’s strong reputation for this skilled and complex type of research.”

In 2024, oncology accounted for more than a quarter of the studies reviewed by Bellberry, while non-clinical trials made up more than 15 per cent of Bellberry reviews.

“Interestingly, we have seen a doubling of the number of social science research activities that Bellberry has reviewed in the last six years from 5% to 10% of total reviews,” said Ms Sproston.

“Australia’s capacity to support the full clinical development pathway is highlighted by the representation of trials in the 2024 CTAR from FIH through to Phase 4, devices, observational, qualitative, social science, registry, audit, and evaluation.”

View our 2024 Clinical Trial Activity Report here

Bellberry is a national, not-for-profit organisation that provides streamlined scientific and ethical reviews of human research established in 2004. It is the 2025 winner of the Championing Health Award in the Telstra Best of Business Awards.

For media queries please contact alisonrogers@bellberry.com.au or on 0488 995 868.